The Canadian Association for Healthcare Reimbursement (CAHR) is hosting a one-day event to discuss two key issues of relevance to the pharmaceutical and life sciences sectors following the October 2015 federal election. Maclean’s magazine’s and event moderator, Paul Wells, will be present to share his knowledge on innovation policy and ... Read More
26
Oct2015
20
Oct2015
Interested in learning more about new developments at the pan-Canadian Pharmaceutical Alliance (pCPA)?
Curious to know more about private payer Product Listing Agreements (PLAs) in Canada?
PDCI Market Access (PDCI) is hosting a free webinar on Friday, October 30, 2015 from 11:00 AM -12:00 PM EDT titled Market Access Climate Change: the ... Read More
16
Oct2015
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the June 2016 “Liste des médicaments”. These meetings will be held between December 7 and December 18, 2015, inclusive.
Meetings will cover the following:
Discussion on clinical studies
Discussion ... Read More
16
Oct2015
In a recent update released on their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced two significant developments:
Québec is now participating in the pCPA; and
The Office of the pCPA (the Office) is now operational.
In Fall 2014, the Provincial/Territorial Health Ministers announced intentions for Québec’s participation in the Federation’s Health Care ... Read More
06
Oct2015
Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for ... Read More
31
Jul2015
Topics covered in the NEWSletter include:
Soliris Pre-Hearing Conference
New Staff Member – Legal Services
Update: Compendium of Policies, Guidelines and Procedures
Part C – Guidelines and Procedures
Schedule 9 – CPI-Adjustment Methodology
Schedule 2 – Comparable Dosage Forms
2016 HDAP Meeting Schedule & Filing Requirements:
February 29
May 2
September 12
November 28
PMPRB Transition to Canada.ca
Update: Germany Recognized Price Source
Summary ... Read More
27
Jul2015
Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable.
Proposed amendments ... Read More
20
Jul2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses
As noted in the June 24th TargetPharma, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are collaborating on a survey to gauge the interest, expectations, and experience associated with private payer product listing agreements (PLAs).
Surveys ... Read More
24
Jun2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations
Private payers – the community of insurers, Pharmacy Benefit Managers (PBMs) and employers in Canada – are starting to build internal competencies aimed at negotiating product listing agreements (PLAs) with pharmaceutical companies. For the past several years, private ... Read More
23
Jun2015
Currently in Canada, switching and substitutability between originator biologics and biosimilars has not been established, however that is not the case internationally. Earlier this year the Dutch Medicines Evaluation Board (MEB) supported switching patients from an innovator biologic to a biosimilar, so long as health professionals are involved and the ... Read More